ABSI - KeyBanc sees opportunity in tech-enabled drug discovery stocks
2023-12-10 13:04:00 ET
More on AbCellera Biologics, Absci, etc.
- AbCellera: Difficult 2023 Suggests Business Model Should Pivot In 2024
- Buy AbCellera Biologics's Revolutionizing AI-Powered Drug Development Platform
- Certara, Inc. 2023 Q3 - Results - Earnings Call Presentation
- AstraZeneca in pact with Absci to develop cancer drug based on AI
- AbCellera Biologics to cut 10% of staff in business shakeup
For further details see:
KeyBanc sees opportunity in tech-enabled drug discovery stocks